Study of Venetoclax, a BCL2 Antagonist, for Patients With Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN)
Dana-Farber Cancer Institute
Dana-Farber Cancer Institute
Dana-Farber Cancer Institute
St. Jude Children's Research Hospital
Mayo Clinic
City of Hope Medical Center
Therapeutic Advances in Childhood Leukemia Consortium